Poland· PL-100021795
EMLA
A lidocain, kombinationen product containing lidocainum + prilocainum, registered in Poland by Aspen Pharma Trading Ltd.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lidocain, kombinationen is registered in 11 of 19 countries.
Countries holding a registration under ATC N01BB52 (lidocain, kombinationen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Lidocain, kombinationen · ATC N01BB52
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Lidocainum + Prilocainum
- Manufacturer
- Aspen Pharma Trading Ltd.
- Country
- Poland (PL)
- ATC code
- N01BB52
- ATC class
- Lidocain, Kombinationen
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909990373314
- gtin05909990373321
- gtin05909990373338
- gtin05909991504472
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lidocain, kombinationen in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesCadira Compliant Blood StatAsclemed USA, Inc.
- United KingdomDenela 5% creamTeva UK Ltd
- SwitzerlandAnesderm
- FranceANESDERM 5 %, crèmePIERRE FABRE MEDICAMENT
- CzechiaEMLAAspen Pharma Trading Limited, Dublin
- FinlandEmlaAspen Pharma Trading Limited
- SwedenEMLA 25 mg/25 mg Medicinskt plåsterAspen Pharma Trading Limited
- SpainANAMAP 25 MG/G + 25 MG/G CREMAGlenmark Arzneimittel Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Emla, Emla Pflaster
- Belgium · Emla, Emla Patch
- Cyprus · Emla, Xylocream
- Czechia · Emla
- Germany · Anesderm, Emla
- Denmark · Emla, Lidocain/Prilocain Idd
- Estonia · Nulbia
- Spain · Anamap®, Anestderma
- Finland · Emla, Oraqix
- France · Anesderm, Emla
- United Kingdom (Northern Ireland) · Emla, Nulbia
- Greece · Emla, Nulbia
- Hungary · Li-Pri
- Ireland · Emla, Oraqix
- Iceland · Emla, Fortacin
- Italy · Emla, Lidocaina E Prilocaina Teva
- Liechtenstein · Fortacin
- Luxembourg · Emla, Emla Patch
- Malta · Emla, Opralix
- Netherlands · Emla, Lidocaïne/Prilocaïne Teva
- Norway · Emla, Fortacin
- Portugal · Emla, Emla Penso
- Romania · Romla
- Sweden · Emla, Oraqix
- Slovakia · Romla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/add2028c-85a0-4d0d-ad34-bd646303cbe5 GET /v1/drugs/add2028c-85a0-4d0d-ad34-bd646303cbe5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Krem",
"source": "urpl",
"strength": "25 mg/g + 25 mg/g",
"packaging": "05909990373314 ¦ Rp ¦ 3609\n1 tuba 5 g ¦ 3 opatrunki okluzyjne\n05909990373321 ¦ Rp ¦ 3611\n5 tub 5 g ¦ 12 opatrunków okluzyjnych\n05909990373338 ¦ Rp ¦ 3612\n1 tuba 30 g\n05909991504472 ¦ Rp ¦ 148260\n1 tuba 5 g ¦ 2 opatrunki okluzyjne",
"substance": "Lidocainum 25 mg/g + Prilocainum 25 mg/g",
"common_name": "Lidocainum + Prilocainum",
"pl_product_id": "100021795",
"pozwolenie_nr": "03733",
"auth_procedure": "MRP",
"authorisation_validity": "Bezterminowe"
}See everything about lidocain, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.